Generation Bio (GBIO) Competitors $0.38 -0.02 (-4.95%) As of 03:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GBIO vs. COYA, SGMT, IVVD, MGNX, BDTX, CTNM, ENTX, KYTX, OPTN, and HLVXShould you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Coya Therapeutics (COYA), Sagimet Biosciences (SGMT), Invivyd (IVVD), MacroGenics (MGNX), Black Diamond Therapeutics (BDTX), Contineum Therapeutics (CTNM), Entera Bio (ENTX), Kyverna Therapeutics (KYTX), OptiNose (OPTN), and HilleVax (HLVX). These companies are all part of the "pharmaceutical products" industry. Generation Bio vs. Coya Therapeutics Sagimet Biosciences Invivyd MacroGenics Black Diamond Therapeutics Contineum Therapeutics Entera Bio Kyverna Therapeutics OptiNose HilleVax Coya Therapeutics (NASDAQ:COYA) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment. Do insiders and institutionals hold more shares of COYA or GBIO? 39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Generation Bio shares are held by institutional investors. 9.8% of Coya Therapeutics shares are held by insiders. Comparatively, 21.8% of Generation Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, COYA or GBIO? Coya Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.76, suggesting that its share price is 176% more volatile than the S&P 500. Does the media favor COYA or GBIO? In the previous week, Coya Therapeutics had 15 more articles in the media than Generation Bio. MarketBeat recorded 15 mentions for Coya Therapeutics and 0 mentions for Generation Bio. Coya Therapeutics' average media sentiment score of 0.41 beat Generation Bio's score of -1.00 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coya Therapeutics Neutral Generation Bio Negative Does the MarketBeat Community believe in COYA or GBIO? Generation Bio received 22 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 96.30% of users gave Coya Therapeutics an outperform vote while only 72.73% of users gave Generation Bio an outperform vote. CompanyUnderperformOutperformCoya TherapeuticsOutperform Votes2696.30% Underperform Votes13.70%Generation BioOutperform Votes4872.73% Underperform Votes1827.27% Which has stronger valuation & earnings, COYA or GBIO? Coya Therapeutics has higher earnings, but lower revenue than Generation Bio. Coya Therapeutics is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$3.69M26.07-$7.99M-$1.07-5.37Generation Bio$24.56M1.04-$126.61M-$1.08-0.35 Is COYA or GBIO more profitable? Coya Therapeutics has a net margin of 0.00% compared to Generation Bio's net margin of -782.86%. Coya Therapeutics' return on equity of -31.63% beat Generation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -31.63% -27.76% Generation Bio -782.86%-104.85%-49.54% Do analysts prefer COYA or GBIO? Coya Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 195.91%. Generation Bio has a consensus price target of $7.33, suggesting a potential upside of 1,819.72%. Given Generation Bio's higher probable upside, analysts clearly believe Generation Bio is more favorable than Coya Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Generation Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCoya Therapeutics beats Generation Bio on 10 of the 17 factors compared between the two stocks. Get Generation Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GBIO vs. The Competition Export to ExcelMetricGeneration BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.61M$6.49B$5.36B$8.40BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.178.9426.6219.74Price / Sales1.04251.31391.30117.36Price / CashN/A65.8538.2534.62Price / Book0.126.456.804.51Net Income-$126.61M$143.98M$3.23B$248.18M7 Day Performance-0.21%3.17%4.02%1.07%1 Month Performance-8.39%7.63%12.19%14.96%1 Year Performance-88.73%-2.38%17.04%6.70% Generation Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GBIOGeneration Bio3.3303 of 5 stars$0.38-5.0%$7.33+1,819.7%-88.6%$25.61M$24.56M-0.17150Negative NewsCOYACoya Therapeutics2.1183 of 5 stars$6.14+1.5%$17.00+176.9%-34.1%$102.69M$3.55M-9.456Trending NewsAnalyst RevisionGap UpSGMTSagimet Biosciences1.9719 of 5 stars$3.31+1.5%$22.40+576.7%-27.6%$101.53M$2M-2.318IVVDInvivyd2.9404 of 5 stars$0.84+29.7%$7.52+797.2%-64.0%$100.50M$25.38M-0.43100Earnings ReportGap DownMGNXMacroGenics3.5702 of 5 stars$1.59+11.2%$7.43+367.2%-63.1%$100.31M$148.34M-1.01430News CoveragePositive NewsAnalyst ForecastBDTXBlack Diamond Therapeutics3.3631 of 5 stars$1.75+6.7%$14.60+734.3%-55.7%$99.19MN/A-1.3290News CoveragePositive NewsGap UpCTNMContineum Therapeutics2.2429 of 5 stars$3.83-1.0%$23.75+520.1%-75.6%$99.09M$50M-0.7831Earnings ReportAnalyst ForecastENTXEntera Bio1.3275 of 5 stars$2.15flat$10.00+365.1%-10.4%$97.66M$181,000.00-8.2720News CoverageGap DownKYTXKyverna Therapeutics2.4134 of 5 stars$2.21+4.7%$18.33+729.6%-83.4%$95.51M$7.03M-0.6496News CoverageAnalyst RevisionGap UpOPTNOptiNose2.9772 of 5 stars$9.42+0.3%$9.00-4.5%-46.7%$95.09M$78.23M-2.24190News CoverageAnalyst ForecastAnalyst RevisionHLVXHilleVax2.5015 of 5 stars$1.89-0.5%$3.00+58.7%-86.1%$94.77MN/A-0.6120News CoveragePositive News Related Companies and Tools Related Companies COYA Alternatives SGMT Alternatives IVVD Alternatives MGNX Alternatives BDTX Alternatives CTNM Alternatives ENTX Alternatives KYTX Alternatives OPTN Alternatives HLVX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GBIO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Generation Bio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Generation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GBIO Stock Free GBIO Stock Alerts